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Prospective evaluation of carotid bruit as a predictor of first stroke in
type II diabetes: The Fremantle Study
Gillett M, Davis WA, Paxon D, et al. Stroke 2003;34:2145-51.
Conclusion: After detection of a carotid bruit in a patient with type II
diabetes the risk for an initial stroke within 2 years is six times that in a patient
with type II diabetes without a carotid bruit.
Summary: The Fremantle Diabetes Study is an observational, prospec-
tive, community based study of diabetes in western Australia. Between 1993
and 1996, 1081 patients with type II diabetes and no history of cerebrovas-
cular disease were recruited and observed until the end of January 2002. Cox
proportional hazards models were used to identify significant cerebrovascu-
lar risk factors for stroke and to determine whether carotid bruit was an
independent predictor of first stroke in patients with type II diabetes.
After study entry, 134 patients (11.3%) developed a first stroke at a
mean of 6.5  2.2 years of follow-up. In the first 2 years after entering the
study, a first stroke occurred in 45 patients (3.8%). After adjustment for
cardiovascular risk factors and other potentially confounding variables, first
stroke in the first 2 years after study entry was strongly predicted by the
presence of carotid bruit (hazard ratio, 6.7; 95% confidence interval, 3.0-
14.9; P  .001). After 2 years of study observation, first stroke was not
associated with carotid bruit (P  .97). Both diastolic blood pressure and
age were also determinants of first stroke in the first 2 years after study entry.
Two years after study entry, age, atrial fibrillation or flutter, and microalbu-
minuria were independent predictors of stroke.
Comment: It might be concluded that patients with type II diabetes
and carotid bruit compose a subgroup who will derive benefit from prophy-
lactic carotid endarterectomy. However, the authors did not report the
degree of carotid stenosis in their patients, and it is not clear that all strokes
involved the extracranial cervical carotid artery. Clearly the data argue for
aggressive risk factor management in patients with type II diabetes and a
carotid bruit. The data, however, do not enable one to conclude that
patients with a carotid bruit and type II diabetes will benefit from prophy-
lactic carotid endarterectomy.
Carotid artery stenosis: Gray-scale and Doppler ultrasound diagnosis.
Society of Radiologists in Ultrasound Consensus Conference
Grant EG, Benson CB, Moneta GL, et al. Radiology 2003;229:340-6.
Conclusion: A consensus conference convened by the Society of
Radiologists in Ultrasound developed a set of criteria for grading internal
carotid artery (ICA) stenosis with Doppler ultrasound scanning. Criteria are
based primarily on ICA peak systolic velocity (PSV) and demonstration of
presence of plaque on gray-scale and color Doppler scans.
Summary: A multidisciplinary panel was charged to develop a set of
reasonable criteria for Doppler diagnosis of ICA stenosis. Criteria proposed
were based on review of the literature and presentations at the conference.
Recommendations included:
1. Use of gray-scale, color Doppler scanning and spectral Doppler ultra-
sound scanning for all carotid artery examinations
2. Stratification of ICA stenoses into six categories:
a. Normal: ICA PSV less than 125 cm/s, with no visible plaque or
intimal thickening
b. Less than 50% stenosis: ICA PSV less than 125 cm/s, with visible
plaque or intimal thickening
c. 50% to 69% stenosis: ICA PSV 125 to 230 cm/s, with visible plaque
d. ICA stenosis greater than 70% to near occlusion: ICA PSV greater
than 230 cm/s, with visible plaque and luminal narrowing on
gray-scale and color images
e. Near occlusion: color Doppler scan showing an extremely narrow
lumen
f. Total occlusion: no detectable lumen on gray-scale ultrasound scans
and no flow on color, power, or spectral Doppler scans
ICA–common carotid artery PSV ratio and ICA end-diastolic velocity
may also be used when it appears that ICA PSV may not represent the extent
of stenosis.
Comment: The conference consisted of panelists from radiology,
neurology, vascular surgery, vascular medicine, and interventional radiol-
ogy, among other specialties. Results represent what the panelists considered
to be reasonable criteria for ICA stenosis. It is suggested that these criteria be
considered by laboratories with insufficient angiographic material for vali-
dation of existing published criteria. The proposed criteria have not been
tested, and do not represent the results of any single publication. Laborato-
ries using published criteria validated locally are urged to continue to use
them.
Subcutaneous Fondaparinux vs intravenous unfractionated heparin in
initial treatment of pulmonary embolism
Matisse Investigators. N Engl J Med 2003;349:1695-1702.
Conclusion: Fondaparinux, given as once daily subcutaneous treat-
ment without monitoring, was as effective and as safe as intravenously
administered unfractionated heparin for treatment of hemodynamically
stable patients with symptomatic pulmonary embolism.
Summary: Fondaparinux is an antithrombotic synthetic agent with
specific anti–factor Xa; activity. It is administered as a single daily subcuta-
neous injection, and does not require monitoring of the anticoagulation
effect. This was an open-label trial of 2213 hemodynamically stable patients
with acute symptomatic pulmonary embolism. Pulmonary embolism was
diagnosed on the basis of findings of computed tomography, pulmonary
angiography, high-probability ventilation perfusion scanning, or a nondiag-
nostic lung scan with either duplex ultrasound scanning or venographic
diagnosis of deep venous thrombosis. Patients received either unfractionated
intravenous heparin via continuous infusion, with a target partial thrombo-
plastin time of one and a half to two and a half times control, or daily
subcutaneous Fondaparinux at a fixed weight-adjusted dose. Both drugs
were given for 5 days until oral anticoagulation therapy resulted in an
international normalized ratio greater than 2.0. The primary end point was
symptomatic recurrent pulmonary embolism or new or recurrent deep
venous thrombosis at 3 months.
New or recurrent pulmonary embolism or deep venous thrombosis
occurred in 42 of 1103 patients receiving Fondaparinux (3.8%) and in 56 of
1110 patients receiving unfractionated heparin (5.0%). Major bleeding
occurred in 1.1% of those given heparin and in 1.3% of those given Fondapa-
rinux. Mortality at 3 months was 5.2% in the Fondaparinux group, and 4.4%
in the heparin group. In the Fondaparinux group 14 patients died of
pulmonary embolism within 3 months, compared with 15 patients in the
heparin group.
Comment: The study demonstrates therapeutic equivalence of
Fondaparinux and continuous infusion of intravenous unfractionated hepa-
rin in the initial management of symptomatic pulmonary embolism in
hemodynamically stable patients. A single daily subcutaneous dose, com-
bined with no need for monitoring of the anticoagulant effect, makes
Fondaparinux an attractive alternative for initial management of uncompli-
cated pulmonary embolism.
Effective treatment of carotid artery stenosis on blood pressure: A
comparison of hemodynamic disturbances after carotid endarterec-
tomy in endovascular treatment
McKebitt FN, Sivaguru A, Venables GS, et al. Stroke 2003;34:2573-82.
Conclusion: Carotid endarterectomy and endovascular treatment of
carotid artery stenosis both affect blood pressure stability during the first 24
hours after the procedure. Compared with preoperative baseline levels,
systolic blood pressure at 6 months is lower in patients who undergo surgery,
and is unchanged in patients who undergo endovascular treatment.
Summary: Periprocedure and long-term blood pressure effects of
carotid endarterectomy and endovascular treatment of carotid artery steno-
sis were studied in patients randomized at a single center in the Carotid and
Vertebral Artery Transluminal Angioplasty Study (CAVATAS). Patients
were randomized to endovascular treatment of carotid stenosis (n  55) or
carotid endarterectomy (n  49). Ambulatory 24-hour blood pressure
monitoring was recorded before carotid intervention and at 24 hours, 1
month and 6 months after intervention. Hypotension and hypertension
were defined as a decrease or increase, respectively, in systolic blood pressure
of 30 mm Hg or greater from baseline blood pressure recordings.
After the procedure, in the first 24 hours hypotension occurred in 76%
of the endovascular group and 75% of the carotid endarterectomy group,
and hypertension occurred in 13% and 11%, respectively. At 1 hour systolic
blood pressure decreased by a mean of 24 mm Hg in the surgical group and
16 mm Hg in the endovascular group; however, the decrease was sustained
only in the endovascular group (P  .0001). At 6 months systolic pressure
was at baseline in the endovascular group, and was 5 mm Hg lower in the
surgical group. Thirty-day stroke and mortality rate was 10.2% in the surgical
group, and 5.5% in the endovascular group. Perioperative neurologic com-
plication was not related to perioperative hemodynamic disturbance.
Comment: The study suggests a difference in blood pressure response
after surgical versus endovascular therapy for carotid artery stenosis. In
surgical patients, however, a specific protocol was used to reverse hypoten-
sion, whereas no specific protocol was used in the stent group. The 6-month
data are difficult to interpret, because there is no follow-up information on
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